Boosting use of SMART inhaler therapy for children with moderate-to-severe asthma
Official title: Single Maintenance And Reliever Therapy Strategies for IMPLementation and Effectiveness (SMART & SIMPLE) Trial
Run by Children's Hospital of Philadelphia · NCT07138027 · Data updated 2026-11-12
This project will test whether adding community health workers and nurse care managers to electronic health record decision support and education helps children ages 5–18 with uncontrolled asthma use single maintenance and reliever therapy (SMART).
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 5 Years to 18 Years |
| Sex | All |
| Enrollment | 18 (estimated) |
| Sponsor | Children's Hospital of Philadelphia Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Status | Recruiting |
| Started | September 3, 2025 |
| Main results expected | August 31, 2027 |
| Study ends | February 29, 2028 |
| Registry record updated | September 18, 2026 |
| Trial ID | NCT07138027 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children ages 5–18 who receive care at participating CHOP primary care clinics, have had an inhaled corticosteroid (with or without LABA) prescription in the past year, and show evidence of uncontrolled asthma are the intended candidates.
✕Probably not a fit
Children who have transferred care away from CHOP or who do not meet the age, medication, or uncontrolled asthma criteria are unlikely to receive benefit from this implementation program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This hybrid Type II implementation-effectiveness trial tests whether adding population health management (PHM) — community health workers and nurse care managers — to an existing electronic health record-based clinical decision support plus education (CDS+) increases clinician prescribing and patient use of SMART therapy in children aged 5–18 with uncontrolled moderate-to-severe asthma. Clinics in the CHOP Pediatric Research Consortium are randomized at the clinic level to receive CDS+ with PHM versus CDS+ alone. Outcomes include SMART adoption and related clinical measures reported at visit, patient, and clinic levels using electronic health record data and implementation metrics. The study focuses on real-world implementation and tracks medication prescribing, fills, and exacerbation-related care.
Why it matters
Potential benefit: If successful, more children with moderate-to-severe asthma could be prescribed and use SMART therapy, potentially reducing exacerbations and simplifying inhaler use.
How similar studies have gone: SMART therapy has demonstrated efficacy and real-world effectiveness in international settings, but implementation efforts in U.S. primary care are limited and this clinic-level PHM addition is a relatively novel implementation approach here.
Who can join: the full rules
Show full inclusion / exclusion criteria
Clinic Inclusion Criteria: * The clinic is a pediatric primary care clinic that is part of the Children's Hospital of Philadelphia (CHOP) Pediatric Research Consortium (PeRC). * The clinic agrees to participate in SMART \& SIMPLE study. Patient Inclusion Criteria: * Ages 5-18 years; * Has clinic visit at participating practice during study interval (sick, well, or follow-up) * Prescribed at least one prescription for an inhaled corticosteroid (ICS) or ICS-long-acting beta agonist (ICS-LABA) for maintenance asthma therapy in the past year; * Evidence of uncontrolled asthma as determined by: (1) uncontrolled Asthma Control Tool score in the past 6 months OR (2) two or more systemic corticosteroids prescribed for an asthma exacerbation in the past 12 months (one occurring in the past 6 months) Clinic Exclusion Criteria: \- The clinic is not willing to participate in SMART \& SIMPLE study interventions. Patient Exclusion Criteria: \- Transferred clinics or left the CHOP Pediatric Care Network.
Where it's running
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Study coordinator: Chén Kenyon, MD, MSHP
- Email: kenyonc@chop.edu
- Phone: 267-426-6339
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
N-WATCH: Can a simple breath device help monitor asthma in kids
This study tests the N-Tidal C device to see if it helps monitor asthma in children aged 5 to under 16 who have wheeze or asthma and are not critically ill.
-
Smart Inhaler Use at Home for Adolescents with IDD and Asthma
This study tests whether daily use of active smart inhalers at home helps adolescents with intellectual disabilities manage asthma better.
-
ASMact: Managing bronchial asthma attacks in children
This study tries a GINA 2025-based staff education and care-standardization approach to see if emergency treatment for children aged 6–17 with acute asthma attacks improves outcomes.
-
Biomarkers and Respiratory Omics in Children: Predicting Disease Course
This study tests whether biomarkers from the lungs and blood can predict how asthma and protracted bacterial bronchitis in children will progress and respond to current therapies.
-
Using technology and school–clinic coordination to improve asthma care for children.
This project will try a tech-enabled program plus school care coordination to help children ages 4–12 with persistent or uncontrolled asthma follow guideline-based treatment and have fewer symptoms and school problems.
-
Implementing SMART asthma care in pediatric primary clinics
This project will test whether electronic medical record decision support plus clinician education helps pediatric clinics adopt SMART single maintenance and reliever inhaler therapy for children ages 5–18 with uncontrolled asthma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.